Pharmacokinetics and Haemodynamics of Felodipine as Monotherapy in Hypertensive Patients

Conclusions

The pharmacokinetic profile of felodipine in patients with hypertension does not differ significantly from that observed previously in healthy volunteers. Similarly, the pharmacokinetics are apparently unaffected by repeated administration. The reductions in systemic blood pressure appear to be correlated to plasma felodipine concentrations and are maintained during long term administration, despite a tachyphylaxis to the unwanted initial tachycardia seen with felodipine. Therefore, felodipine would seem to provide a suitable alternative to conventional therapy in the treatment of mild to moderate hypertension.